DuoCAR20.19.22-D95

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug NameDuoCAR20.19.22-D95
Drug Alias NameDuoCAR20.19.22-D95
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulatorsCD22 modulators +[4] 
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20CD22
Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Kansas Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Kansas Medical Center
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A